share_log

Revance Therapeutics | 8-K: Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update

SEC ·  May 9 13:16
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more